Andere Sprachen Lipidor AB Deutsche Boerse AG

Aktien

A2PHEZ

SE0012558617

L7R

Verzögert Deutsche Boerse AG Andere Börsenplätze 09:46:25 17.07.2024			% 5 Tage	% 1. Jan.
0,0042 ^EUR	0,00 %		+2.000,00 %	-87,20 %

22.05.	Lipidor AB (publ) meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
22.04.	Lipidor AB (publ) verschiebt die Veröffentlichung des Geschäftsberichts für 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Lipidor resolves on a directed issue of shares to underwriters in connection with the completion of the rights issue	01.07.
Lipidor's rights issue and share capital reduction are registered – conversion of BTU into shares and warrants	25.06.
Lipidor announces final outcome in the rights issue	13.06.
Lipidor announces preliminary outcome in the rights issue	12.06.
Last day of trading in unit rights in Lipidor's rights issue	07.06.
Bulletin from the Annual General Meeting of Lipidor AB (publ)	05.06.
Lipidor invites to digital presentations with Q&A	29.05.
Today the subscription period in Lipidor's rights issue begins	29.05.
Lipidor publishes prospectus due to upcoming rights issue of units	24.05.
Lipidor AB (publ) publishes interim report for Q1 2024	22.05.
Lipidor AB Reports Earnings Results for the First Quarter Ended March 31, 2024	22.05.
Bulletin from the Extraordinary General Meeting of Lipidor AB (publ)	21.05.
Lipidor AB (publ) publishes annual report for 2023	15.05.
NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (PUBL)	07.05.
Lipidor AB announces new date for publication of Annual Report 2023	22.04.
Lipidor AB Postpones the Publication of Annual Report for 2023	22.04.
NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (PUBL)	10.04.
Lipidor resolves on a rights issue of approximately SEK 58.0 million and enters into a co-investment agreement which secures funding for the implementation of the upcoming phase III study	10.04.
Lipidor completes planned divestment of shares in Emollivet	26.03.
Lipidor announces approval for start of Phase III clinical trial of psoriasis candidate AKP02G2	21.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Lipidor AB Deutsche Boerse AG

Aktien

A2PHEZ

SE0012558617

L7R

Andere Sprachen

Filter